Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy

Cancer

Volumn 103, Issue 9, 2005, Pages 1916-1924

  Caggiano, Vincent ^a   Weiss, Richard V ^b   Rickert, Timothy S ^b   Linde Zwirble, Walter T ^b  

^a Sutter Medical Center   (United States)

^b Health Process Management LLC   (United States)

Author keywords

Chemotherapy; Cost; Neutropenia; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; FEMALE; HEALTH CARE COST; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; INCIDENCE; INTERNATIONAL CLASSIFICATION OF DISEASES; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPENIA; PRIORITY JOURNAL; SOLID TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COSTS AND COST ANALYSIS; FEMALE; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; SURVIVAL RATE;

EID: 17644379037     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20983     Document Type: Article

References (48)

1. Silber JH, Fridman, M, DiPaola RS, Erder MH, Pauly MV, Fox KR. First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early stage breast cancer therapy. J Clin Oncol. 1998;16:2392-2400.
2. Bodey GP. Infection in cancer patients: a continuing association. Am J Med. 1986;81(Suppl 1A):11-26.
3. Bodey GP, Buckley M, Sathe, YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia, Ann Intern Med. 1966;64:328-340.
4. Weber RJ. Pharmacoeconomic issues in the use of granulocyte-macrophage colony-stimulating factor for bone marrow transplantation or chemotherapy-induced neutropenia. Clin Ther. 1993;15:180-191.
5. Lyman GH, Kuderer N, Greene J, Balducci L. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer. 1998;34:1857-1864.
6. Livingston, RB. Dose intensity and high dose therapy: two different concepts. Cancer. 1994;74:1177-1183.
7. Petros WP, Peters WP. Hematopoietic colony-stimulating factors and dose intensity. Semin Oncol. 1993;20:94-99.
8. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984;2:1281-1288.
9. Lyman GH, Morrison VA, Dale DC, Crawford J, Delgado DJ, Fridman M. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma. 2003;44:2069-2076.
10. Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer. 2003;98:2402-2409.
11. Chrischilles EA, Link BK, Scott SD, Delgado DJ, Fridman M. Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin's lymphoma. Cancer Control. 2003;10:396-403.
12. Dixon DO, Neilan B, Jones SE, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol. 1986;4:295-305.
13. Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol. 1990;8:963-977.
14. Lepage E, Gisselbrecht C, Haioun C, et al, for the Groupe d'Etude des Lymphomes de l'Adulte. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. Ann Oncol 1993;4:651-656.
15. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995;332:901-906.
16. American College of Surgeons. National Cancer Data Base, Commission on Cancer, American College of Surgeons. Benchmark Reports, version 1.1. January 17, 2003.
17. Howe JR, Karnell LH, Menck HR, Scott-Conner C. Adenocarcinoma of the small bowel: review of the National Cancer Data Base 1985-1995. Cancer. 1999;86:2693-2706.
18. Kennedy BJ, Fremgen AM, Menck HR. The National Cancer Data Base Report on Hodgkin's disease for 1985-1989 and 1990-1994. Cancer. 1998;83:1041-1047.
19. Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a National Cancer Data Base report. Cancer. 1999;86:1867-1876.
20. Chang J. Chemotherapy dose reduction and delay in clinical practice: evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer. 2000;36:S11-S14.
21. Gandhi SK, Arguelles L, Boyer JG. Economic impact of neutropenia and febrile neutropenia in breast cancer: estimates from two national databases. Pharmacotherapy. 2001;21:684-690.
22. Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol. 2002;20:4636-4642.
23. American Cancer Society. Cancer facts and figures: 2003. Available from URL; www.cancer.org/downloads/stt/ caff2003pwsecured.pdf (accessed September 9, 2003).
24. Uyl-de Groot CA, Vellenga E, Rutten FFH. An economic model to assess the savings from a clinical application of haematopoietic growth factors. Eur J Cancer. 1996;32A:57-62.
25. Kuderer NM, Cosler L, Crawford J, Dale DC, Lyman GH. Cost and mortality associated with febrile neutropenia in adult cancer patients [abstract 998]. Proc Am Soc Clin Oncol. 2002;21:250a.
26. Kuderer NM, Cosler L, Crawford J, Dale DC, Lyman GH, for the ANC Study Group. Mortality and economic impact of hospitalization with febrile neutropenia in patients with breast cancer: analysis of a nationwide database [abstract 106]. Proc Am Soc Clin Oncol. 2003;22:27.
27. Lyman GH, Kuderer NM, Agboola O, Crawford J, Dale D, for the ANC Study Group. The epidemiology and economics of neutropenia in hospitalized cancer patients: data from the University Health System Consortium [abstract 1813]. Blood. 2001;98:432a.
28. State of California, Office of Statewide Health Planning and Development. Patient discharge data, 1999. Sacramento: State of California, Office of Statewide Health Planning and Development.
29. Agency for Healthcare Administration. Hospital inpatient data file, State of Florida. State of Florida, Agency for Health Care Administration, 1999. Tallahassee: State of Florida, Agency for Healthcare Administration.
30. Executive Office of Health. Fiscal year 1996 hospital case mix data base. The Commonwealth of Massachusetts, Executive Office of Health and Human Services, 1999. Boston: Commonwealth of Massachusetts, Executive Offices of Health and Human Services.
31. Department of Health and Human Services. Discharge data UB-92 YTD tape file: State of New Jersey, Department of Health and Senior Services, 1999. Trenton: State of New Jersey, Department of Health and Senior Services.
32. New York State Department of Health SPARCS. "Expanded administrative releasable" data. New York: State of New York Department of Health, 1999. Albany: State of New York, Department of Health.
33. Virginia Health Information. Public use file-PUF1 patient level data. State of Virginia, Virginia Health Information, 1999. Richmond: State of Virginia.
34. Comprehensive Hospital Abstract Reporting System (CHARS). CHARS public data file. State of Washington, Department of Health, 1999. Olympia: State of Washington, Department of Health.
35. Centers for Medicare and Medicaid Services. 1999 CMS provider specific file. Washington, DC: Centers for Medicare and Medicaid Services, 1999.
36. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303-1310.
37. United States Bureau of Census. Population Estimates Program, Report CB97-64. Washington, DC: United States Bureau of Census, 1990.
38. Ventura SJ, Martin JA, Curtin SC, Menaker F, Hamilton BE. Births: final data for 1999. National Vital Statistics Reports, April 17, 2001;49(1). Atlanta; Centers for Disease Control and Prevention, 2001.
39. National Cancer Institute. Surveillance, Epidemiology, and End Results initiative (SEER). Available from URL: http://seer.cancer.gov, 2001. [accessed Nov. 5, 2002].
40. Epelbaum R, Haim N, Ben-Shahar M, Ron Y, Cohen Y. Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. Isr J Med Sci. 1998;24:533-538.
41. Morrison VA, Picozzi V, Scott S, et al. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkins lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma. 2001;2:47-56.
42. Intragumtornchai T, Sutheesophon J, Sutcharitchan P, Swasdikul D. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2000;37:351-360.
43. Weiner N, Fridman M, Steinberg D, Sparks J, Larsen C, Tronic B. A model to predict chemotherapy related neutropenic events in intermediate and high grade lymphoma (IHL) patients (PTS) [abstract 361]. Blood. 1998;92:88a.
44. Kloess M, Wunderlich A, Pfreundschuh M, Loeffler M. Prognostic factors for hematotoxicity of CHOP-like multicycle chemotherapy in aggressive NHL [abstract 362). Blood. 1998;92(Suppl 1):89A.
45. Kloess M, Wunderlich A, Truemper L, Pfreundschuh M, Loeffler M. Predicting hematotoxicity in multicycle chemotherapy [abstract 381]. Blood. 1999;94(Suppl 1):87a.
46. Scott SD, Chrischilles EA, Link BK, Delgado DJ, Fridman M, Lyman GH. Time to first febrile neutropenia (FN) among early stage breast cancer (ESBC) patients. Presented at the American College of Clinical Pharmacologists Spring Forum. Palm Springs, California, April 27-30, 2003.
47. Thomas ES, Rivera EM, Erder MH, Fridman M, Frye D, Hortobagyi GN. Using first cycle nadir absolute neutrophil count (FCNANC) as a risk factor for neutropenic events: a validation study [abstract 144). Proc Am Soc Clin Oncol. 2001;20:37a.
48. Savvides P, Terrin N, Erban J, Selker HP. Development and validation of a patient-specific predictive instrument for the need for dose reduction in chemotherapy for breast cancer: a potential decision aid for the use of myeloid growth factors. Support Care Cancer. 2003;11:313-320.